Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist,arachydonilcyclopropylamide (ACPA),in the rat amygdala is mediated through the D1 and D2 dopaminergic systems
Restricted accessResearch articleFirst published online January, 2011
Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist,arachydonilcyclopropylamide (ACPA),in the rat amygdala is mediated through the D1 and D2 dopaminergic systems
In the present study the influence of the dopaminergic system(s) of the amygdala on the anxiolytic-like effect of the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in male Wistar rats was investigated. An elevated plus-maze test of anxiety was used to assess anxiety-like behaviors. The results showed that bilateral intra-amygdala injections of ACPA (0.125, 1.25 and 5 ng/rat) and the mixed dopamine D1/D2 receptor agonist, apomorphine, at different doses (0.001, 0.01 and 0.1 µg/rat) increased percentage open arm time (%OAT) and percentage open arm entries (%OAE), indicating an anxiolytic-like effect for both of the drugs. In contrast, intra-amygdala administration of the dopamine D1 receptor antagonist SCH23390 (0.5 and 1 µg/rat) and the dopamine D2 receptor antagonist, sulpiride (2 and 3 µg/rat) decreased %OAT and %OAE, suggesting an anxiogenic-like effect for both of the drugs. Interestingly, pretreatment with a sub-effective dose of apomorphine (0.0005 µg/rat) increased, while SCH23390 (0.25 µg/rat) and sulpiride (1.5 µg/rat) decreased the anxiolytic-like effect of ACPA. It can be concluded that the dopaminergic system of the amygdala may be involved, at least partly, in the anxiolytic-like effects induced by ACPA in the rat amygdala.
AmaralDGCorbettBA. (2003) The amygdala, autism and anxiety. Novartis Found Symp251: 177–187.
2.
AzadSCEderMMarsicanoGLutzBZieglgansbergerWRammesG. (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem10: 116–128.
3.
BartoszykGD. (1998) Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci62: 649–663.
4.
BerrenderoFMaldonadoR. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl)163: 111–117.
5.
BrandaoMLAnseloniVZPandossioJEDe AraujoJECastilhoVM. (1999) Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci Biobehav Rev23: 863–875.
6.
De la MoraMPCardenas-CachonLVazquez-GarciaM. (2005) Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat. Neurosci Lett377: 101–105.
7.
De OliveiraARReimerAEBrandaoML. (2006) Dopamine D2 receptor mechanisms in the expression of conditioned fear. Pharmacol Biochem Behav84: 102–111.
8.
DomeniciMRAzadSCMarsicanoG. (2006) Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci26: 5794–5799.
9.
FurlanSMBrandaoML. (2001) Effects of systemic injections of dopaminergic agents on the habituation of rats submitted to an open field test. Neuropsychobiology43: 83–90.
10.
GarciaAMMartinezRBrandaoMLMoratoS. (2005) Effects of apomorphine on rat behavior in the elevated plus-maze. Physiol Behav85: 440–447.
11.
GardnerEL. (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav81: 263–284.
12.
GiuffridaAParsonsLHKerrTMRodriguez de FonsecaFNavarroMPiomelliD. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci2: 358–363.
13.
HillardCJMannaSGreenbergMJ. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther289: 1427–1433.
14.
InoueTIzumiTLiXBKitaichiYNakagawaSKoyamaT. (2005) Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear. Eur J Pharmacol519: 253–258.
15.
JaworskiJNGonzalesRARandallPK. (2001) Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. Eur J Pharmacol418: 201–206.
16.
KatonaIRanczEAAcsadyL. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci21: 9506–9518.
17.
LavioletteSRGraceAA. (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci63: 1597–1613.
18.
LeDouxJE. (2000) Emotion circuits in the brain. Annu Rev Neurosci23: 155–184.
19.
LiXHoffmanAFPengXQLupicaCRGardnerELXiZX. (2009) Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl)204: 1–11.
20.
MarcoEMPerez-AlvarezLBorcelE. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol15: 21–27.
21.
MarcoEMViverosMP. (2009) Functional role of the endocannabinoid system in emotional homeostasis. Rev Neurol48: 20–26.
22.
MartinABFernandez-EspejoEFerrerB. (2008) Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology33: 1667–1679.
23.
MicaleVCristinoLTamburellaA. (2009) Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiol Dis36: 70–80.
24.
MoreiraFALutzB. (2008) The endocannabinoid system: emotion, learning and addiction. Addict Biol13: 196–212.
25.
O’NeillCEvers-DonnellyANicholsonDO’BoyleKMO’ConnorJJ. (2009) D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry. J Neurochem108: 545–551.
26.
OnaiviESGreenMRMartinBR. (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther253: 1002–1009.
27.
PatelSCravattBFHillardCJ. (2005) Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology30: 497–507.
28.
PatelSRademacherDJHillardCJ. (2003) Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther306: 880–888.
29.
PaxinosGWatsonC. (2006) The rat brain in stereotaxic coordinates, 6th ed. Amsterdam: Academic Press.
30.
PhelpsEALeDouxJE. (2005) Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron48: 175–187.
31.
PiomelliD. (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci4: 873–884.
32.
PolissidisAChouliaraOGalanopoulosA. (2009) Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol27: 1–17.
33.
PonnusamyRNissimHABaradM. (2005) Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem12: 399–406.
34.
RezayofAHosseiniSSZarrindastMR. (2009) Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res202: 171–178.
35.
RodgersRJJohnsonNJ. (1995) Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav52: 297–303.
36.
RodgersRJNikulinaEMColeJC. (1994) Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav49: 985–995.
37.
RosenkranzJAGraceAA. (2002) Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci22: 324–337.
38.
RotzingerSVaccarinoFJ. (2003) Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci28: 171–181.
39.
RubinoTGuidaliCViganoD. (2008) CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology54: 151–160.
40.
SahPFaberESLopez De ArmentiaMPowerJ. (2003) The amygdaloid complex: anatomy and physiology. Physiol Rev83: 803–834.
41.
SperlaghBWindischKAndoRDSylvester ViziE. (2009) Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. Neurochem Int54: 452–457.
42.
SwansonLWPetrovichGD. (1998) What is the amygdala?Trends Neurosci21: 323–331.
43.
TalalaenkoANAbrametsIAStakhovskii YuVShekhovtsovAAChernikovAVShevchenkoSL. (1994) The role of dopaminergic mechanisms on the brain in various models of anxious states. Neurosci Behav Physiol24: 284–288.
44.
TimothyCCostallBSmytheJW. (1999) Effects of SCH23390 and raclopride on anxiety-like behavior in rats tested in the black-white box. Pharmacol Biochem Behav62: 323–327.
45.
TroncosoACOsakiMYMasonSBorelliKGBrandaoML. (2003) Apomorphine enhances conditioned responses induced by aversive stimulation of the inferior colliculus. Neuropsychopharmacology28: 284–291.
46.
TzavaraETWadeMNomikosGG. (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci23: 9374–9384.
47.
ViverosMPMarcoEMFileSE. (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav81: 331–342.
48.
ZahmDSTrimbleM. (2008) The dopaminergic projection system, basal forebrain macrosystems, and conditioned stimuli. CNS Spectr13: 32–40.
49.
ZarrindastMRMoghadamAHRostamiPRoohbakhshA. (2005a) The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety. Behav Pharmacol16: 643–649.
50.
ZarrindastMRNasehiMRostamiPRezayofAFazli-TabaeiS. (2005b) Repeated administration of dopaminergic agents in the dorsal hippocampus and morphine-induced place preference. Behav Pharmacol16: 85–92.
51.
ZarrindastMRRezayofASahraeiHHaeri-RohaniARassouliY. (2003) Involvement of dopamine D1 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. Brain Res965: 212–221.
52.
ZarrindastMRSarahroodiSArziAKhodayarMJTaheri-ShalmaniSRezayofA. (2008) Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behaviour: interaction with the opioid system. Behav Pharmacol19: 716–723.
